

CLAIMS

1. Polymorph 1 of bilastin characterised by X-ray crystallography analysis with crystal parameters of approximately the following:

5

Crystallograph system	Monoclinical	
Spatial group	P2 (1)/c	
Crystal size	0.56 x 0.45 x 0.24 mm	
Cell dimension	a=23.38 (5) A angstrom	$\alpha = 90^\circ$
	b=8.829 (17) A	$\beta = 90^\circ$
	c=12.59 (2) A	$\gamma = 90^\circ$
Volume	2600 A ³	
Z, calculated density	4, 1.184 mg/m ³	

10

15

2. Polymorph 1 of bilastin according to Claim 1, distinguished in that it has an infrared spectrum in potassium bromide with the following bands:

Wavelength (cm⁻¹)

20

3057

2929

2883

2857

2797

1666

25

1481

1431

1346

1326

1288

973

945

829

- 5 3. Polymorph 1 of bilastin according to Claim 1, distinguished because it has an infrared spectrum in potassium bromide like the one shown in Figure 1.
- 10 4. Procedure to prepare polymorph 1 of bilastin according to Claims 1, 2 and 3 that consists in heating the bilastin obtained as described in US patent 5,877,187 in a solvent selected from short chained alcohols, preferably isopropyl alcohol and n-butanol, acetone and its mixtures.
- 15 5. Procedure to prepare polymorph 1 from bilastin according to Claims 1, 2 and 3 that consists in heating polymorphs 2 and 3 of bilastin or its mixtures, in a solvent selected from short chained alcohols, preferably isopropyl alcohol and n-butanol, acetone and its mixtures.
- 20 6. Polymorph 1 of bilastin according to Claim 1 for antihistaminic and antiallergic use.
7. Polymorph 1 of bilastin according to Claim 2 for antihistaminergic and antiallergic use.
- 25 8. Polymorph 1 of bilastin according to Claim 3 for antihistaminergic and antiallergic use.

9. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 1 and an acceptable pharmaceutical excipient.

5 10. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 2 and an acceptable pharmaceutical excipient.

10 11. A pharmaceutical preparation consisting in an effective amount of polymorph 1 of bilastin according to Claim 3 and an acceptable pharmaceutical excipient.

15 12. Use of polymorph 1 of bilastin according to Claim 1 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.

20 13. Use of polymorph 1 of bilastin according to Claim 2 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.

14. Use of polymorph 1 of bilastin according to Claim 3 to prepare a medicinal product to treat allergic reactions and pathological processes mediated by histamine.